4D Molecular Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3
4D Molecular Therapeutics, Inc. (FDMT) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-15.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 · last filed 2023-03-15
- 4D Molecular Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2022-12-31 was $0.00.
- 4D Molecular Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2022-09-30 was $0.00.
- 4D Molecular Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2022-06-30 was $0.00.
- 4D Molecular Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2022-03-31 was $0.00.
- 4D Molecular Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2022 was $0.00.
- 4D Molecular Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2021 was $0.00.
- 4D Molecular Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2020 was $0.00.
- 4D Molecular Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2019 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $0.00 derived: sum of 3 quarters · filed 2023-03-15 | $0.00 10-K · filed 2023-03-15 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 4 quarters · filed 2023-03-15 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-03-15 | $0.00 derived: sum of 4 quarters · filed 2023-03-15 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $0.00 derived: sum of 3 quarters · filed 2023-03-15 | $0.00 derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $0.00 derived: sum of 3 quarters · filed 2023-03-15 | $0.00 10-K · filed 2023-03-15 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-28 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |